Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma
Diagnostics · 28.06.2025 · 15 (13) · 1655
DOI: 10.3390/diagnostics15131655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 28.06.2025. Verfasst von Faris Alrumaihi. Beteiligte Einrichtung: Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Graduate Studies and Scientific Research at Qassim University.
Abstract (Originalsprache)
The global prevalence of hepatocellular carcinoma (HCC) is getting worse, leading to an urgent need for improved diagnostic and prognostic strategies. Liquid biopsy, which analyzes circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), and extracellular vesicles (EVs), has emerged as a minimally invasive and promising alternative to traditional tissue biopsy. These biomarkers can be detected using sensitive molecular techniques such as digital PCR, quantitative PCR, methylation-specific assays, immunoaffinity-based CTC isolation, nanoparticle tracking analysis, ELISA, next-generation sequencing, whole-genome sequencing, and whole-exome sequencing. Despite several advantages, liquid biopsy still has challenges like sensitivity, cost-effectiveness, and clinical accessibility. Reports highlight the significance of multi-analyte liquid biopsy panels in enhancing diagnostic sensitivity and specificity. This approach offers a more comprehensive molecular profile of HCC, early detection, and tracking therapeutic treatment, particularly in those cases where single-analyte assays and imaging fail. The technological advancement in the isolation and analysis of CTC, cell-free nucleic acids, and EVs is increasing our understanding of extracting genetic information from HCC tumors and discovering mechanisms of therapeutic resistance. Furthermore, crucial information on tumor-specific transcriptomic and genomic changes can be obtained using cfRNA and cfDNA released into the peripheral blood by tumor cells. This review provides an overview of current liquid biopsy strategies in HCC and their use for early detection, prognosis, and monitoring the effectiveness of HCC therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
ORCID-Profile: Faris Alrumaihi
Förderung
- Deanship of Graduate Studies and Scientific Research at Qassim University
Zitieren
APA
Alrumaihi, F. (2025). Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma. Diagnostics, 15(13), 1655. https://doi.org/10.3390/diagnostics15131655
Vancouver
Alrumaihi F. Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma. Diagnostics. 2025;15(13):1655. doi:10.3390/diagnostics15131655
BibTeX
@article{Alrumaihi2025,
author = {Alrumaihi, Faris},
title = {Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {13},
pages = {1655},
doi = {10.3390/diagnostics15131655}
}
EUVIMED